Bevacizumab for the Management of Pediatric Radiation Necrosis: a Narrative Review

Document Type

Article

Publication Date

2-5-2026

Publication Title

Current oncology reports

Keywords

Bevacizumab; Central nervous system tumors; Pediatric radiation necrosis; Radiation oncology; Vascular endothelial growth factor (VEGF)

Abstract

PURPOSE OF REVIEW: Radiation necrosis (RN) presents a significant challenge in the treatment of pediatric central nervous system tumors. This narrative review synthesizes current evidence on the use of bevacizumab (BEV) for managing pediatric RN, drawing from case reports, retrospective reviews, and prospective clinical trials. While high-quality prospective data remain limited, emerging evidence suggests that BEV may be effective in alleviating both clinical symptoms and radiographic manifestations of RN in pediatric patients.

RECENT FINDINGS: This review explores the pathophysiology of RN, BEV’s mechanism of action, and existing evidence on the use of BEV in pediatric RN. Emerging evidence suggests that bevacizumab may provide symptomatic relief and radiographic improvement in pediatric patients with RN.

SUMMARY: By addressing current knowledge gaps, the aim is to provide insight into the potential role of BEV in improving outcomes for pediatric patients with RN.

PubMed ID

41642455

Volume

28

Issue

1

First Page

4

Last Page

4

Find It @ Sladen

Share

COinS